US4301153A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Heparin preparation
Assignee: Riker Laboratories Inc
•
Filing: 1978-03-30
•
Granted: 1981-11-17
•
Expires: 1998-03-30
Abstract
Abstract A heparin preparation which exhibits elevated anticoagulant activity and a process for producing the preparation. Conventional heparin exhibiting characteristic anticoagulant activity and molecular heterogeneity is incubated with antithrombin-heparin cofactor extracted from plasma. A portion of the heparin forms a complex with the cofactor. The uncomplexed heparin fraction is then separated from the complexed fraction, and the complexed fraction is broken down to produce cofactor and an active form of heparin.
Inventors
- 👤 Robert D. Rosenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:03
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K38/00; A61K38/005; C; C08; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0075
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
89 words
A process for producing heparin characterized by elevated anticoagulant activity, said process comprising the steps of: A. providing a heparin preparation of animal tissue origin which exhibits molecular heterogeneity and anticoagulant activity; B. providing AT cofactor extracted from mammalian plasma; C. incubating the heparin preparation with the AT cofactor to complex a portion of the heparin with the cofactor; D. separating a complex of heparin and cofactor from the remainder of the heparin preparation; and, E. separating the cofactor from the complex to produce heparin having improved anticoagulant activity.
Claim 2
Dependent Claim
89 words
A process for producing heparin characterized by elevated anticoagulant activity, said process comprising the steps of: A. providing a heparin preparation of animal tissue origin which exhibits molecular heterogeneity and anticoagulant activity; B. providing AT cofactor extracted from mammalian plasma; C. incubating the heparin preparation with the AT cofactor to complex a portion of the heparin with the cofactor; D. separating a complex of heparin and cofactor from the remainder of the heparin preparation; and, E. separating the cofactor from the complex to produce heparin having improved anticoagulant activity.
Claim 3
Dependent Claim
32 words
The process as set forth in claim 1 wherein the heparin preparation provided in step A is extracted from tissue selected from the group consisting of beef, porcine, sheep, and whale tissue.
Claim 4
Dependent Claim
30 words
The process as set forth in claim 1 wherein the heparin produced in step E has at least twice the anticoagulant activity of the heparin preparation provided in step A.
Claim 5
Dependent Claim
22 words
The process as set forth in claim 1 wherein the AT heparin cofactor provided in step B is extracted from human plasma.
Claim 6
Dependent Claim
49 words
A potentiated heparin preparation prepared from heparin of animal tissue origin which has been complexed with AT cofactor, separated from heparin uncomplexed with AT cofactor, and separated from the heparin AT cofactor complex to yield a heparin preparation having greater anticoagulant activity than heparin from the animal tissue origin.
Claim 7
Dependent Claim
49 words
A potentiated heparin preparation prepared from heparin of animal tissue origin which has been complexed with AT cofactor, separated from heparin uncomplexed with AT cofactor, and separated from the heparin AT cofactor complex to yield a heparin preparation having greater anticoagulant activity than heparin from the animal tissue origin.
Claim 8
Dependent Claim
93 words
A process for inhibiting coagulation of blood, said process comprising the steps of: A. providing a heparin preparation of animal tissue origin which exhibits molecular heterogeneity and anticoagulant activity; B. providing AT cofactor extracted from mammalian plasma; C. incubating the heparin preparation with the AT cofactor to complex a portion of the heparin with the cofactor; D. separating a complex of heparin and cofactor from the remainder of the heparin preparation; E. separating the cofactor from the complex to produce heparin having improved anticoagulant activity; and, F. mixing the potentiated heparin with blood.
Claim 9
Dependent Claim
93 words
A process for inhibiting coagulation of blood, said process comprising the steps of: A. providing a heparin preparation of animal tissue origin which exhibits molecular heterogeneity and anticoagulant activity; B. providing AT cofactor extracted from mammalian plasma; C. incubating the heparin preparation with the AT cofactor to complex a portion of the heparin with the cofactor; D. separating a complex of heparin and cofactor from the remainder of the heparin preparation; E. separating the cofactor from the complex to produce heparin having improved anticoagulant activity; and, F. mixing the potentiated heparin with blood.
Claim 10
Dependent Claim
22 words
The process as set forth in claim 6 wherein the potentiated heparin is mixed with blood by injecting the potentiated heparin subcutaneously.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-11-16 | 1985-05-18 | 1985-11-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-11-16 | 1989-05-18 | 1989-11-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-11-16 | 1993-05-18 | 1993-11-17 | $7700.00 | Window Closed / Lapsed |